Skip to main content
SpringerLink
Log in

Docetaxel

A Review of its Pharmacodynamic and Pharmacokinetic Properties and Therapeutic Efficacy in the Management of Metastatic Breast Cancer

  • Drug Evaluation
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Summary

Docetaxel is a member of the taxoid class of antineoplastic agents. Its mechanism of action is primarily related to its ability to enhance microtubule assembly and to stabilise microtubules by preventing their depolymerisation, thus disrupting normal cell division. Docetaxel has significant cytotoxic activity against human breast cancer cell lines and freshly explanted human breast cancer cells in vitro. It has also shown activity in mice against mammary tumours and human mammary tumour xenografts.

Docetaxel has been investigated in the treatment of patients with advanced and/or metastatic breast cancer in European and North American phase II trials using an initial dose of 100 mg/m infused over 1 hour every 3 weeks. As first-line treatment, monotherapy with docetaxel was associated with complete and partial response rates of 5 to 16% and 49 to 53%, respectively, with an overall (complete plus partial) response rate of 54 to 68%. The median overall survival time of patients in one study was ≥71 weeks. Docetaxel monotherapy has shown impressive activity as second-line therapy in patients with metastatic breast cancer who had relapsed while receiving adjuvant therapy or who had progressive disease following previous treatment, with overall response rates of 53 and 58% reported in 2 studies.

A number of issues need to be addressed before the ultimate place of docetaxel in the management of metastatic breast cancer is fully established. The efficacy of docetaxel compared with standard agents and in combination regimens and its effect on quality-of-life aspects require further evaluation. Nevertheless, docetaxel is a promising new agent which has produced impressive clinical results and should be considered an alternative second-line treatment of patients with metastatic breast cancer.

Pharmacodynamic Properties

The cytotoxic activity of docetaxel is believed to primarily result from its ability to enhance microtubule assembly and to stabilise microtubules, preventing their depolymerisation and thus preventing normal cell division. This mechanism is supported by in vitro studies which demonstrate that docetaxel reduces the lag time for the initiation of polymerisation, decreases the minimum concentration of tubulin required for microtubule assembly and induces polymerisation in the near absence of the microtubule assembly cofactor guanosine 5-triphosphate.

In vitro studies in human breast cancer cell lines or in freshly explanted human breast cancer cells show docetaxel has significant cytotoxic activity, which in most instances is greater than that reported for paclitaxel in fresh cell isolates. Docetaxel had in vivo activity against 3 of 4 murine mammary tumours studied and, at the highest tolerated dose, produced complete regression in 100% (30/30) of nude mice with human mammary tumour xenografts. Docetaxel dernonstrated schedule-dependent in vitro synergism against human breast cancer cell lines when combined with edatrexate. Synergism has also been observed in mice with mammary adenocarcinoma receiving docetaxel plus cyclophosphamide.

Acquired resistance to docetaxel occurs via two identified mechanisms; one is associated with the expression of the multidrug resistance phenotype, whereas the other is associated with alterations in tubulin. Cross-resistance between docetaxel and other antitumour agents has been reported in many, but not all, cell lines which express the multidrug resistance phenotype, which suggests that cross-resistance does not automatically occur in cells expressing this gene.

Pharmacokinetic Properties

At doses ≥70 mg/m2, the pharmacokinetic profile of docetaxel fitted a 3-compartment model. The maximum plasma concentration (Cmax) and the area under the plasma concentration-time curve (AUC) were proportional to dose. In 2 studies, Cmax values were 2.41 and 3.67 mg/L and AUC values were 5.93 and 4.59 mg/L · h after doses of 100 mg/m2 administered over 1 hour. The drug is 93 to 94% protein bound.

Docetaxel is primarily metabolised by cytochrome P450 (CYP) enzymes, and 4 largely inactive major metabolites have been identified. The predominant route of elimination is metabolism then faecal excretion via the biliary tract. A population pharmacokinetics study in 547 patients who received docetaxel in phase II trials estimated total body clearance and elimination half-life to be, respectively, 21 L/h · m2 and 11.2 hours. Clearance appears to be reduced in patients with moderate hepatic dysfunction.

The in vitro metabolism of docetaxel is reduced by drugs which are substrates of the CYP3A4 isozyme (erythromycin, ketoconazole, nifedipine, troleandomycin, testosterone, orphenadrine and midazolam). Some in vitro inhibition of docetaxel metabolism was also produced by vinorelbine, vinblastine and doxorubicin; however, other drugs including cisplatin, fluorouracil, cyclophosphamide and etoposide had little effect on the in vitro metabolism of docetaxel. When docetaxel was administered prior to cisplatin as part of sequential therapy, the white blood cell DNA-adduct levels of cisplatin were significantly lower than when cisplatin was administered first.

Therapeutic Efficacy in Metastatic Breast Cancer

In dose-finding studies in patients with various solid tumours, the maximum tolerated dose of docetaxel was 80 to 115 mg/m2 per course of therapy. Based on these results, a dose of 100 mg/m2 infused once every 3 weeks was considered to be optimal for phase II trials in Europe and North America. In Japan, a lower dosage (60 mg/m2/3 weeks) was used.

Four trials have evaluated docetaxel 100 mg/m2 every 3 weeks as first-line therapy in 137 evaluable patients with advanced and/or metastatic breast cancer. Complete response was reported in 5 to 16% of patients and partial response in 49 to 53%. The overall response rate (complete plus partial response) ranged from 54 to 68%. One study reported no difference in response rates between patients who had received prior adjuvant chemotherapy and those who had not. In this study, the median duration of response was ≥44 weeks and the median overall survival time was ≥71, weeks. In 2 studies which used a dosage of 75 mg/m2 every 3 weeks, the overall response rates were 40 and 52%.

Docetaxel 100 mg/m2 /3 weeks has also been evaluated as second-line therapy in patients with histologically and/or cytologically verified advanced and/or metastatic breast cancer who had relapsed while receiving adjuvant therapy or who had progressive disease following previous treatment. In 2 studies which evaluated a total of 69 patients with anthracycline- or anthracenedione-resistant breast cancer, 3 patients experienced a complete response, and the partial response rates were 49 and 53%.

In Japanese trials evaluating docetaxel 60 mg/m every 3 to 4 weeks, complete and partial response rates ranged, respectively, from 4 to 7% and 37 to 50% in 186 patients, most of whom had received prior chemotherapy.

Tolerability

Neutropenia is the primary dose-limiting adverse effect of docetaxel after short term infusion, occurring in >90% of patients receiving docetaxel 100 mg/m2. However, neutropenia is generally rapidly reversible, with only 14.8% of patients requiring hospitalisation and/or treatment with antibiotics. Fluid retention, usually characterised by peripheral oedema, is related to the cumulative dose of docetaxel. However, premedication with corticosteroids delays the onset of this adverse event. Hypersensitivity reactions occur in 31.3% of patients, are usually observed within minutes of administration of docetaxel, and are reversible upon discontinuing the infusion. Premedication decreases the severity of hypersensitivity reactions and discontinuation of therapy is required only rarely. Various types of cutaneous events including mucositis, desquamation and nail changes have been reported in a large proportion of patients (up to 70%). Other reported adverse events include peripheral neuropathy, alopecia, asthenia, nausea and diarrhoea.

Dosage and Administration

The recommended initial intravenous dose of docetaxel is 100 mg/m2 infused over 1 hour every 3 weeks. Pretreatment with corticosteroids is recommended to reduce the incidence of docetaxel-related fluid retention and the severity of hypersensitivity reactions. Dosage reductions are recommended in patients with severe drug-related toxicity and in those with hepatic dysfunction.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Gelmon K. The taxoids: paclitaxel and docetaxel. Lancet 1994 Nov 5; 344: 1267–72

    Article  PubMed  CAS  Google Scholar 

  2. Kaye SB. Taxoids. Eur J Cancer A 1995; 31A (5): 824–6

    Article  PubMed  CAS  Google Scholar 

  3. Bissery M-C, Nohynek G, Sanderink G-J, et al. Docetaxel (Taxotere®): a review of preclinical and clinical experience. Part I: preclinical experience. Anticancer Drugs 1995 Jun; 6: 339–68

    CAS  Google Scholar 

  4. Spencer CM, Faulds D. Paclitaxel: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of cancer. Drugs 1994 Nov; 48 (5): 794–847

    Article  PubMed  CAS  Google Scholar 

  5. Ringle I, Horwitz SB. Studies with RP56976 (taxotere): a semisynthetic analogue of taxol. J Natl Cancer Inst 1991 Feb 20; 83: 288–91

    Article  Google Scholar 

  6. Diaz JF, Andreu JM. Assembly of purified GDP-tubulin into microtubules induced by Taxol and Taxotere: reversibility, ligand stoichiometry, and competition. Biochemistry 1993 Mar 23; 32: 2747–55

    Article  PubMed  CAS  Google Scholar 

  7. Kumar N. Taxol-induced polymerization of purified tubulin. J Biol Chem 1981; 256: 10435–41

    PubMed  CAS  Google Scholar 

  8. Andreu JM, Díaz JF, Gil R, et al. Solution structure of Taxotereinduced microtubules to 3-nm resolution. The change in protofilament number is linked to the binding of the taxol side chain. J Biol Chem 1994 Dec 16; 269: 31785–92

    CAS  Google Scholar 

  9. Fromes Y, Gounon P, Bissery MC, et al. Differential effects of Taxol and Taxotere (RP56976, NSC628503) on Tau and MAP2 containing microtubules [abstract no. 3055]. Proceedings of the American Association Cancer Research 1992; 33: 511

  10. Hennequin C, Giocanti N, Favaudon V. S-phase specificity of cell killing by docetaxel (Taxotere) in synchronised HeLa cells. Br J Cancer 1995 Jun; 71: 1194–8

    Article  PubMed  CAS  Google Scholar 

  11. Vogel M, Hilsenbeck SG, Depenbrock H, et al. Preclinical activity of taxotere (RP 56976, NSC 628503) against freshly explanted clonogenic human tumour cells: comparison with taxol and conventional antineoplastic agents. Eur J Cancer A 1993; 29A (14): 2009–14

    Article  PubMed  CAS  Google Scholar 

  12. Hanauske A-R, Degen D, Hilsenbeck S-G, et al. Effects of Taxotere and taxol on in vitro colony formation of freshly explanted human tumor cells. Anticancer Drugs 1992 Apr; 3: 121–4

    Article  PubMed  CAS  Google Scholar 

  13. Hill BT, Whelan RDH, Shellard SA, et al. Differential cytotoxic effects of docetaxel in a range of mammalian tumor cell lines and certain drug resistant sublines in vitro. Invest New Drugs 1994; 12 (3): 169–82

    Article  PubMed  CAS  Google Scholar 

  14. Riou J-F, Naudin A, Lavelle F. Effects of taxotere on murine and human tumor cell lines. Biochem Biophys Res Commun 1992 Aug 31; 187: 164–70

    Article  PubMed  CAS  Google Scholar 

  15. Untch M, Untch A, Sevin B-U, et al. Comparison of paclitaxel and docetaxel (Taxotere) in gynecologic and breast cancer cell lines with the ATP-cell viability assay. Anticancer Drugs 1994 Feb; 5: 24–30

    Article  PubMed  CAS  Google Scholar 

  16. Braakhuis BJM, Hill BT, Dietel M, et al. In vitro antiproliferative activity of docetaxel (Taxotere®), paclitaxel (Taxol) and cisplatin against human tumour and normal bone marrow cells [abstract no. 149-0348]. Anticancer Res 1994 Jan–Feb; 14: 205–8

    CAS  Google Scholar 

  17. Zoli W, Flamigni A, Frassineti GL, et al. In vitro activity of taxol and taxotere in comparison with doxorubicin and cisplatin on primary cell cultures of human breast cancers. Breast Cancer Res Treat 1995 Apr; 34: 63–9

    Article  PubMed  CAS  Google Scholar 

  18. Kelland LR, Abel G. Comparative in vitro cytotoxicity of taxol and Taxotere against cisplatin-sensitive and -resistant human ovarian carcinoma cell lines. Cancer Chemother Pharmacol 1992 Sep; 30: 444–50

    Article  PubMed  CAS  Google Scholar 

  19. Bissery MC, Vrignaud P, Bayssas M, et al. Docetaxel (RP 56976, Taxotere®) efficacy as a single agent or in combination against mammary tumors in mice [abstract no. 1946]. Proceedings of the American Association Cancer Research 1994 Mar; 35: 327

    Google Scholar 

  20. Bissery M-C, Guénard D, Guéritte-Voegelein F, et al. Experimental antitumor activity of Taxotere (RP 56976, NSC 628503), a taxol analogue. Cancer Res 1991 Sep 15; 51: 4845–52

    PubMed  CAS  Google Scholar 

  21. Dykes DJ, Bissery MC, Harrison Jr. SD, et al. Response of human tumor xenografts in athymic nude mice to docetaxel (RP 56976, Taxotere®). Invest New Drugs 1995; 13: 1–11

    CAS  Google Scholar 

  22. Lavelle F, Bissery MC, Riou JF, et al. Preclinical evaluation of docetaxel (Taxotere). Semin Oncol 1995 Apr; 22 Suppl. 4: 3–16

    CAS  Google Scholar 

  23. Riou JF, Petitgenet O, Aynie I, et al. Establishment and characterization of docetaxel (Taxotere®) resistant human breast carcinoma (Calc18/TXT) and murine leukemic (P388/TXT) cell lines. Proceedings of the American Association Cancer Research 1994; 35: 399

    Google Scholar 

  24. Chou T-C, Otter GM, Sirotnak FM. Schedule-dependent synergism of taxol or taxotere with edatrexate against human breast cancer cells in vitro. Cancer Chemother Pharmacol 1996; 37: 222–8

    Article  PubMed  CAS  Google Scholar 

  25. Bissery MC, Vrignaud P, Bayssas M, et al. Taxotere® synergistic combination with cyclophosphamide, etoposide and 5-fluorouracil in mouse tumor models. Proceedings of the American Association Cancer Research 1993; 34: 299

    Google Scholar 

  26. Manthey CL, Qureshi N, Stutz PL, et al. Lipopolysaccharide antagonists block Taxol-induced signaling in murine macrophages. J Exp Med 1993 Aug 1; 178: 695–702

    Article  PubMed  CAS  Google Scholar 

  27. Burkhart CA, Berman JW, Swindell CS, et al. Relationship between the structure of taxol and other taxanes on induction of tumor necrosis factor-α gene expression and cytotoxicity. Cancer Res 1994 Nov 15; 54: 5779–82

    PubMed  CAS  Google Scholar 

  28. Choy H, Rodriguez F, Wilcox B, et al. Radiation sensitizing effects of Taxotere® (RP 56976) [abstract no. 2991]. Proceedings of the American Association Cancer Research 1992; 33: 500

  29. Aapro MS, Zulian G, Alberto P, et al. Phase I and pharmacokinetic study of RP 56976 in a new ethanol-free formulation of taxotere [abstract no. 208]. Ann Oncol 1992; 3 Suppl. 5: 53

    Google Scholar 

  30. Burris H, Irvin R, Kuhn J, et al. Phase I clinical trial of taxotere administered as either a 2-hour or 6-hour intravenous infusion. J Clin Oncol 1993 May; 11: 950–8

    PubMed  CAS  Google Scholar 

  31. Extra J-M, Rousseau F, Bruno R, et al. Phase I and pharmacokinetic study of taxotere (RP 56976; NSC 628503) given as a short intravenous infusion. Cancer Res 1993 Mar 1; 53: 1037–42

    PubMed  CAS  Google Scholar 

  32. Rhône-Poulenc Rorer. Docetaxel product monograph. 2nd edition, 1996.

  33. Launay-Iliadis MC, Bruno R, Cosson V, et al. Population pharmacokinetics of docetaxel during phase I studies using nonlinear mixed-effect modeling and nonparametric maximum-likelihood estimation. Cancer Chemother Pharmacol 1995; 37: 47–54

    Article  PubMed  CAS  Google Scholar 

  34. Marre F, De Sousa G, Placidi M, et al. Élucidation des voies de biotransformation hépatique du Taxotère au moyen de modèles in vitro d’origine humaine [abstract]. Bull Cancer 1993; 80 (6): 527

    Google Scholar 

  35. Commerçon A, Bourzat J-D, Bézard J-D, et al. Partial synthesis of major human metabolites of docetaxel. Tetrahedron 1994; 50 (34): 10289–98

    Article  Google Scholar 

  36. Bruno R, Sanderink GJ. Pharmacokinetics and metabolism of Taxotere™ (docetaxel). Cancer Surv 1993; 17: 305–13

    PubMed  CAS  Google Scholar 

  37. de Valeriola D, Brassinne C, Gaillard C, et al. Study of excretion balance, metabolism and protein binding of C14radiolabelled Taxotere (TXT) (RP56976, NSC628503) in cancer patients [abstract no. 2221]. Proceedings of the American Association Cancer Research 1993 March; 34: 373

    Google Scholar 

  38. Royer I, Monsarrat B, Sonnier M, et al. Metabolism of docetaxel by human cytochromes P450: interactions with paclitaxel and other antineoplastic drugs. Cancer Res 1996; 56: 58–65

    PubMed  CAS  Google Scholar 

  39. Schellens JHM, Ma J, Bruno R, et al. Pharmacokinetics of cisplatin and Taxotere® (docetaxel) and WBC DNA-adduct formation of cisplatin in the sequence Taxotere®/cisplatin and cisplatin/Taxotere® in a phase I/II study in solid tumor patients [abstract]. Proc Am Soc Clin Oncol 1994 Mar; 13: 132

    Google Scholar 

  40. Bissett D, Setanoians A, Cassidy J, et al. Phase I and pharmacokinetic study of taxotere (RP 56976) administered as a 24-hour infusion. Cancer Res 1993 Feb 1; 53: 523–7

    PubMed  CAS  Google Scholar 

  41. Pazdur R, Newman RA, Newman BM, et al. Phase I trial of Taxotere: five-day schedule. J Natl Cancer Inst 1992 Dec 2; 84: 1781–8

    Article  PubMed  CAS  Google Scholar 

  42. Tomiak E, Piccart MJ, Kerger J, et al. Phase I study of docetaxel administered as a 1-hour intravenous infusion on a weekly basis. J Clin Oncol 1994 Jul; 12: 1458–67

    PubMed  CAS  Google Scholar 

  43. Taguchi T, Furue H, Niitani H, et al. Phase I clinical trial of RP56976 (docetaxel) a new anticancer drug [in Japanese]. Gan to Kagaku Ryoho 1994 Sep; 21: 1997–2005

    PubMed  CAS  Google Scholar 

  44. Miller AB, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment. Cancer 1981 Jan; 47: 207–14

    Article  PubMed  CAS  Google Scholar 

  45. Chevallier B, Fumoleau P, Kerbrat P, et al. Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer. J Clin Oncol 1995 Feb; 13: 314–22

    PubMed  CAS  Google Scholar 

  46. Dieras V, Chavallier B, Kerbrat P, et.al. A mulicentre phase II study of docetaxel 75 mg/m2 as first-line chemotherapy for patients with advanced breast cancer: report of the Clinical Screening Group of the EORTC. Br J Cancer. In press.

  47. Fumoleau P, Chevallier B, Kerbrat P, et al. A multicentre phase II study of the efficacy and safety of docetaxel as first-line treatment of advanced breast cancer: Report of the Clinical Screening Group of the EORTC. Ann Oncol In press

  48. Hudis CA, Seidman AD, Crown JPA, et al. Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer. J Clin Oncol 1996 Jan; 14 (1): 58–65

    PubMed  CAS  Google Scholar 

  49. Trudeau ME, Eisenhauer EA, Higgins BP, et al. Docetaxel in patients with metastatic breast cancer: a phase II study of the National Cancer Institute of Canada-Clinical Trials Group. J Clin Oncol 1996 Feb; 14 (2): 422–8

    PubMed  CAS  Google Scholar 

  50. Dieras V, Fumoleau P, Chevallier B, et al. Second EORTC-Clinical Screening Group (CSG) phase II trial of Taxotere® (docetaxel) as first line chemotherapy in advanced breast cancer (ABC) [abstract]. Proc Am Soc Clin Oncol 1994 Mar; 13: 78

    Google Scholar 

  51. Ravdin PM, Burris III HA, Cook G, et al. Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer. J Clin Oncol 1995 Dec; 13 (12): 2879–85

    PubMed  CAS  Google Scholar 

  52. ten Bokkel Huinink WW, Prove AM, Piccart M, et al. A phase II trial with docetaxel (Taxotere®) in second line treatment with chemotherapy for advanced breast cancer: a study of the EORTC Early Clinical Trials Group. Ann Oncol 1994 Jul; 5: 527–32

    PubMed  Google Scholar 

  53. Valero V, Holmes FA, Walters RS, et al. Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracyclin-resistant metastatic breast cancer. J Clin Oncol 1995 Dec; 13 (12): 2886–94

    PubMed  CAS  Google Scholar 

  54. Bellet R, Riva A, Ravdin P, et al. Docetaxel (Taxotere): a new active agent in antracycline resistant metastatic breast cancer. Rhône-Poulenc Rorer (data on file).

  55. Adachi I, Watanabe T, Takashima S, et al. A late phase II study of RP56976 (docetaxel) in patients with advanced or recurrent breast cancer. Br J Cancer 1996; 73: 210–6

    Article  PubMed  CAS  Google Scholar 

  56. Taguchi T. An early phase II clinical study of RP56976 (docetaxel) in patients with cancer of the gastrointestinal tract [in Japanese]. Gan to Kagaku Ryoho 1994 Oct; 21: 2431–7

    PubMed  CAS  Google Scholar 

  57. Taguchi T, Mori S, Abe R, et al. Late phase II clinical study of RP56976 (docetaxel) in patients with advanced/recurrent breast cancer [in Japanese]. Gan to Kagaku Ryoho 1994 Nov; 21: 2625–32

    PubMed  CAS  Google Scholar 

  58. Mouridsen HT. Systemic therapy of advanced breast cancer Drugs; 1992 (44): Suppl

  59. Gruia G, Misset JL, Giachetti S, et al. A phase I–II study of Taxotere (TXTR) in combination with Adriamycin (AD) as first line chemotherapy (CT) in patients with metastatic breast cancer [abstract no. 258]. Proc Am Soc Clin Oncol 1995; 14: 140

    Google Scholar 

  60. Zalcberg J, Bishop JF, Webster LK, et al. A phase I trial of the combination Taxotere (docetaxel) and cisplatin in patients with advanced non-small cell lung cancer (NSCLC) [abstract no. P773]. Ann Oncol 1994; 5 Suppl. 8: 154

    Google Scholar 

  61. Cole JT, Gralla RJ, Marques CB, et al. Phase I-II study of cisplatin + docetaxel (Taxotere) in non-small cell lung cancer (NSCLC) [abstract no. 1087]. Proc Am Soc Clin Oncol 1995; 14: 357

    Google Scholar 

  62. Verweij J, Planting AST, van der Burg MEL, et al. A phase I study of docetaxel (Taxotere) and cisplatin in patients with solid tumors [abstract no. 386]. Proc Am Soc Clin Oncol 1994 Mar; 13: 148

    Google Scholar 

  63. Burris III HA, Fields S, Peacock N. Docetaxel (Taxotere) in combination: a step forward. Semin Oncol 1995 Dec; 95(22) Suppl. 6: 35–40

    Google Scholar 

  64. Cortes JE, Pazdur R. Docetaxel. J Clin Oncol 1995 Oct; 13: 2643–55

    PubMed  CAS  Google Scholar 

  65. Fumoleau P, Chevallier B, Dieras V, et al. Safety evaluation of two doses of Taxotere® (docetaxel) without routine premedication as first line in advanced breast cancer (ABC)-EORTC Clinical Screening Group (CSG) report [abstract]. Proc Am Soc Clin Oncol 1994 Mar; 13: 109

    Google Scholar 

  66. Van Oosterom AT, Schriivers D. Docetaxel (Taxotere®), a review of preclinical and clinical experience. Part II: clinical experience. Anticancer Drugs 1995 Jun; 6: 356–68

    Google Scholar 

  67. Jaffrézou J-P, Laurent G. Docetaxel (Taxotere): current status and clinical prospects. Expert Opin Invest Drug 1995 Dec; 4 (12): 1185–95

    Article  Google Scholar 

  68. Tomiak E, Kerger J, Lips S, et al. Unexpected pleural changes observed in patients treated with Taxotere (RP 56976): a new drug toxicity? [abstract]. Ann Oncol 1992 Nov; 3 Suppl. 5: 48

    Google Scholar 

  69. Piccart MJ, Klijn J, Paridaens R, et al. Steroids do reduce the severity and delay the onset of docetaxel (DXT) induced fluid retention: final results of a randomized trial of the EORTC investigational drug branch for breast cancer (IDBBC) [abstract]. Eur J Cancer 1995 Nov; 31A Suppl. 5: S75

    Article  Google Scholar 

  70. Oulid-Aïssa D, Béhar A, Spielmann M, et al. Management of fluid retention syndrome in patients treated with Taxotere® (docetaxel): effect of premedication [abstract]. Proc Am Soc Clin Oncol 1994 Mar; 13: 465

    Google Scholar 

  71. Balmaceda C, Forsyth P, Seidman AD, et al. Peripheral neuropathy in patients receiving taxotere chemotherapy [abstract]. Ann Neurol 1993 Aug; 34: 313

    Google Scholar 

  72. New PZ, Barohn R. Neurotoxicity of Taxotere [abstract]. Neurology 1993 Apr; 43 Suppl. 2: A191

    Google Scholar 

  73. Van den Bent MJ, Hilkens PHE, Verwey J, et al. Docetaxel induces a mild dose-dependent sensory neuropathy [abstract]. Neurology 1995 Apr; 45 Suppl. 4: 322

    Google Scholar 

  74. Hilkens PHE, Verweij J, Stoter G, et al. Peripheral neurotoxicity induced by docetaxel. Neurology 1996 Jan; 46: 104–8

    Article  PubMed  CAS  Google Scholar 

  75. Cavaletti G, Tredici G. Platinum compounds and taxoids: is combination neurotoxicity a possibility?. Cancer J 1995 Mar–Apr; 8: 46–7

    Google Scholar 

  76. Wanders J, Schrijvers D, Bruntsch U, et al. The EORTC-ECTG experience with acute hypersensitivity reactions in Taxotere studies [abstract]. Proc Am Soc Clin Oncol 1993 Mar; 12: 73

    Google Scholar 

  77. Eisenhauer EA, Lu F, Muldal A, et al. Predictors and treatment of docetaxel (D) toxic effects [abstract]. Ann Oncol 1994; 5 Suppl. 5: 202

    Google Scholar 

  78. Wanders J, Van Oosterom A, Gore M, et al. Taxotere toxicity — protective effects of premedication [abstract no. S206]. Eur J Cancer 1993; 29A Suppl. 6: 1148

    Google Scholar 

  79. Zimmerman GC, Keeling JH, Burris HA, et al. Acute cutaneous reactions to docetaxel, a new chemotherapeutic agent. Arch Dermatol 1995 Feb; 131: 202–6

    Article  PubMed  CAS  Google Scholar 

  80. Battafarano DF, Zimmerman GC, Older SA, et al. Docetaxel (Taxotere) associated scleroderma-like changes of the lower extremities: a report of three cases. Cancer 1995 Jul 1; 76: 110–5

    Article  PubMed  CAS  Google Scholar 

  81. Harris JR, Lippman ME, Veronesi U, et al. Breast cancer (first of three parts). N Engl J Med 1992 July 30; 327 (5): 319–28

    Article  PubMed  CAS  Google Scholar 

  82. McPherson K, Steel CM, Dixon JM. Breast cancer-epidemiology, risk factors, and genetics. BMJ 1994 Oct 15; 309: 1003–6

    Article  PubMed  CAS  Google Scholar 

  83. Early Breast Cancer Trialist’s Collaborative Group. Sytemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31 000 recurrances and 24 000 deaths among 75 000 women. Lancet 1992; 339: 1–15,71-85

    Google Scholar 

  84. Sledge Jr GW, Antman KM. Progress in chemotherapy for metastatic breast cancer. Semin Oncol 1992 June; 19 (3): 317–32

    PubMed  Google Scholar 

  85. Rubens RD. Improving treatment for advanced breast cancer. Cancer Surv 1993; 18: 199–208

    PubMed  CAS  Google Scholar 

  86. Hutton J, Brown R, Borowitz M, et al. A new decision model for cost-utility comparisons of chemotherapy in recurrent metastatic breast cancer. PharmacoEconomics. In press

Download references

Author information

Authors and Affiliations

  1. Adis International Limited, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, Auckland 10, New Zealand

    Bret Fulton & Caroline M. Spencer

Authors
  1. Bret Fulton
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Caroline M. Spencer
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

Various sections of the manuscript reviewed by: I. Adachi, Medical Oncology Division, National Cancer Center Hospital, Tokyo, Japan; D. Bisset, Aberdeen Royal Hospitals NHS Trust, Aberdeen, Scotland; B.J.M. Braakhuis, Department of Otolaryngology/Head and Neck Surgery, Free University Hospital, Amsterdam, The Netherlands, E.A. Eisenhauer, National Cancer Institute of Canada, Queen’s University, Kingston, Ontario, Canada; G.N. Hortobagyi, Department of Breast and Gynecologic Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA; C.A. Hudis, Division of Solid Tumor Oncology, Memorial Sloan-Kettering Cancer Center, New York, New York, USA; I.R. Judson, Department of Medical Oncology, CRC Centre for Cancer Therapeutics at The Institute of Cancer Research, Sutton, England; F.M. Muggia, Division of Medical Oncology, Kenneth Norris Jr Comprehensive Cancer Center, University of Southern California, Los Angeles, California, USA; R. Pazdur, Division of Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA; M.J. Piccart, Unité de Chimiothérapie, Institut Jules Bordet, Brussels, Belgium; J.H.M Schellens, Department of Medical Oncology, Dr Daniel den Hoed Kliniek, Rotterdam, The Netherlands.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fulton, B., Spencer, C.M. Docetaxel. Drugs 51, 1075–1092 (1996). https://doi.org/10.2165/00003495-199651060-00011

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-199651060-00011

Keywords

Search

Navigation